Trastuzumab Deruxtecan Exceeds Saudi Cost-Effectiveness Thresholds for Metastatic Breast Cancer
A health economics model found trastuzumab deruxtecan is clinically effective but not cost-effective for HER2-low metastatic breast cancer under current ...




















